AptarGroup Expands Equity Incentive Plan

CRYSTAL LAKE, IL – AptarGroup, Inc. (NYSE:ATR), a leader in the dispensing systems industry with a market capitalization of $10 billion and annual revenue of $3.55 billion, announced the expansion of its 2018 Equity Incentive Plan following approval from its stockholders at the Annual Meeting on May 7, 2025. According to InvestingPro data, the company maintains a GREAT financial health score, reflecting its strong market position. The amendment increases the number of shares available for issuance by 1,000,000. This decision was part of the resolutions passed during the meeting, which also included the election of directors and other corporate governance matters.

The stockholders’ approval of the amendment to the 2018 Plan was detailed in the company’s definitive proxy statement filed with the SEC on March 28, 2025. The full text of the amended plan is filed as Exhibit 10.1 to the current report on Form 8-K. InvestingPro analysis reveals that AptarGroup has maintained dividend payments for 33 consecutive years, with a current dividend yield of 1.19%.

In addition, the election of three directors to serve until the 2028 Annual Meeting was confirmed. The directors, Giovanna Kampouri Monnas, Isabel Marey-Semper, and Stephan B. Tanda, were elected with the majority of votes cast for their appointment. The results of the votes for each director were as follows: Monnas received 53,841,380 votes for, Marey-Semper received 53,041,404 votes for, and Tanda received 56,950,109 votes for their respective elections.

The company’s executive compensation also received advisory approval, with 55,201,530 votes for the compensation plan. Furthermore, the stockholders approved the amendment to the 2018 Plan with 55,973,606 votes in favor.

Lastly, the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 58,926,203 votes for the appointment.

The information presented in this article is based on AptarGroup’s recent 8-K filing with the Securities and Exchange Commission. InvestingPro subscribers can access comprehensive analysis, including 8 additional ProTips and detailed financial metrics in the Pro Research Report, providing deeper insights into AptarGroup’s market position and future prospects.

In other recent news, AptarGroup Inc . reported its first-quarter earnings for 2025, revealing a modest beat in earnings per share (EPS) while experiencing a decline in revenue compared to expectations. The company’s adjusted EPS was $1.20, surpassing the projected $1.16, but revenue fell short at $887 million against the anticipated $929.07 million. Analysts from firms like Bank of America and Baird engaged in discussions about AptarGroup’s performance, particularly noting strong demand in their Pharma segment, which saw a 3% increase in core sales. The company also continued to innovate with new product launches in Germany and China.

Despite facing challenges such as a higher effective tax rate of 25.8% compared to 20.5% last year, AptarGroup reported a 3% year-over-year growth in adjusted EBITDA, reaching $183 million. The company generated a free cash flow of $26 million and returned approximately $110 million to shareholders through dividends and share repurchases. Looking ahead, AptarGroup provided guidance for the second quarter of 2025, with an EPS range of $1.56 to $1.64 and an expected effective tax rate of 19-21%.

Analysts from Raymond (NSE:RYMD) James and Jefferies explored the impact of tariffs and the company’s strategic positioning in the face of economic uncertainties. CEO Stephane Tanda emphasized AptarGroup’s resilience and commitment to essential products, stating that the company’s strong North American footprint and global supply chain structure provide a competitive edge. Overall, AptarGroup remains focused on supporting its growth trajectory through innovation and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.